ロード中...
Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
PURPOSE: We aimed to assess the patient-reported outcome (PRO) and efficacy of add-on low-dose antimuscarinic therapy in over-active bladder (OAB) patients with suboptimal response to 4-week treatment with beta 3 agonist monotherapy (mirabegron, 50 mg). MATERIALS AND METHODS: We enrolled OAB patient...
保存先:
| 出版年: | Investig Clin Urol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
The Korean Urological Association
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5494350/ https://ncbi.nlm.nih.gov/pubmed/28681036 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4111/icu.2017.58.4.261 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|